SciBX
Science-Business eXchange

THE DISTILLERY

## This week in therapeutics

| Indication | Target/marker/pathway | Summary | Licensing status | Publication and contact information |
|---|---|---|---|---|
| **Cancer** | | | | |
| Non-Hodgkin's lymphoma (NHL) | Pim-2 (PIM2); eukaryotic translation initiation factor 4A1 (EIF4A1) | Patient tissue and mouse studies suggest protein translation inhibitors could help treat chemoresistant PIM2-expressing lymphomas. In a mouse model of PIM2-expressing NHL, rapamycin plus an inhibitor of EIF4A1, which blocks protein translation, increased disease-free survival compared with rapamycin alone. Next steps include developing better inhibitors of cap-dependent translation.<br><br>*SciBX* 4(36); doi:10.1038/scibx.2011.1017<br>Published online Sept. 15, 2011 | Patent application filed; available for licensing | Schatz, J.H. *et al. J. Exp. Med.*; published online Aug. 22, 2011; doi:10.1084/jem.20110846<br>**Contact:** Hans-Guido Wendel, Memorial Sloan-Kettering Cancer Center, New York, N.Y.<br>e-mail: wendelh@mskcc.org |